- Ambrose, Nalini;
- Amin, Alpesh;
- Anderson, Brian;
- Bertagnolli, Monica;
- Campion, Francis;
- Chow, Dan;
- Danan, Risa;
- DArinzo, Lauren;
- Drews, Ashley;
- Erlandson, Karl;
- Fitzgerald, Kristin;
- Gaspar, Fraser;
- Gong, Carlene;
- Hanna, George;
- Hawley, Heather;
- Jones, Stephen;
- Lopansri, Bert;
- Mullen, Ty;
- Musser, James;
- OHoro, John;
- Piantadosi, Steven;
- Pritt, Bobbi;
- Razonable, Raymund;
- Rele, Shyam;
- Roberts, Seth;
- Sandmeyer, Suzanne;
- Stein, David;
- Te, Jerez;
- Vahidy, Farhaan;
- Webb, Brandon;
- Welch, Nathan;
- Wood, Alexander;
- Yttri, Jennifer
BACKGROUND: Limited research has studied the influence of social determinants of health (SDoH) on the receipt, disease risk, and subsequent effectiveness of neutralizing monoclonal antibodies (nMAbs) for outpatient treatment of COVID-19. OBJECTIVE: To examine the influence of SDoH variables on receiving nMAb treatments and the risk of a poor COVID-19 outcome, as well as nMAb treatment effectiveness across SDoH subgroups. DESIGN: Retrospective observational study utilizing electronic health record data from four health systems. SDoH variables analyzed included race, ethnicity, insurance, marital status, Area Deprivation Index, and population density. PARTICIPANTS: COVID-19 patients who met at least one emergency use authorization criterion for nMAb treatment. MAIN MEASURE: We used binary logistic regression to examine the influence of SDoH variables on receiving nMAb treatments and risk of a poor outcome from COVID-19 and marginal structural models to study treatment effectiveness. RESULTS: The study population included 25,241 (15.1%) nMAb-treated and 141,942 (84.9%) non-treated patients. Black or African American patients were less likely to receive treatment than white non-Hispanic patients (adjusted odds ratio (OR) = 0.86; 95% CI = 0.82-0.91). Patients who were on Medicaid, divorced or widowed, living in rural areas, or living in areas with the highest Area Deprivation Index (most vulnerable) had lower odds of receiving nMAb treatment, but a higher risk of a poor outcome. For example, compared to patients on private insurance, Medicaid patients had 0.89 (95% CI = 0.84-0.93) times the odds of receiving nMAb treatment, but 1.18 (95% CI = 1.13-1.24) times the odds of a poor COVID-19 outcome. Age, comorbidities, and COVID-19 vaccination status had a stronger influence on risk of a poor outcome than SDoH variables. nMAb treatment benefited all SDoH subgroups with lower rates of 14-day hospitalization and 30-day mortality. CONCLUSION: Disparities existed in receiving nMAbs within SDoH subgroups despite the benefit of treatment across subgroups.
